Released Mar 15, 2017, after the close
10-K filed Mar 15, 2017, 74 days after period end · 0001390478-17-000020
Q4 2016 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income$352.00K$352.00K derivedN/M vs Q4 2015N/M vs Q3 2016
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived$8,744,000N/M
Operating Cash Flowderived$25,065,000N/M
Free Cash Flowderived$25,065,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2016dderived from reported figures | Q4 2015dderived from reported figures | Q4 2014dderived from reported figures | Q4 2013 |
|---|---|---|---|---|
| Revenue | — | — | $3.20M | $1.44M |
| Net Income | $352.00K | -$19.68M | -$7.96M | -$5.52M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR